Lincomycin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Lincomycin
- Pharmacist Assessment Report
- Lincomycin: From Pneumococcal, Staphylococcal and Streptococcal Infections to Polyclonal Hyperviscosity Syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Lincomycin: From Pneumococcal, Staphylococcal and Streptococcal Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Lincomycin is a lincosamide antibiotic. The TxGNN model (deep learning) predicts it may be effective for polyclonal hyperviscosity syndrome, but there are 0 clinical trials and 0 publications supporting this prediction, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pneumococcal, staphylococcal and streptococcal infections (relations recorded in the knowledge graph; the local licence records contain no approved indication text) |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9914 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Lincomycin is known as a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Polyclonal hyperviscosity syndrome arises from elevated serum immunoglobulins or other proteins, for example in autoimmune disease or chronic infection. It is not a bacterial-driven process that an antibiotic would directly treat. No credible mechanistic link was identified between lincomycin and this condition.
The high TxGNN score (0.9914) is a computational prediction only. It comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Two other top-ranked predictions, hyperamylasemia (0.9914) and congenital analbuminemia (0.9906), show the same pattern: high scores, no supporting studies, and no plausible mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
At least 20 licences exist, and the list below may be partial. All shown are valid single-ingredient products. The licence records contain no approved indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 125534 | Liod 300mg Injection | Vial of 2 ml injection | Not stated in licence record |
| Registration No. 129176 | Lincozin 250mg Capsule | Strip of 10 capsules | Not stated in licence record |
| Registration No. 130092 | Linocin 250mg Capsule | Strip of 10 capsules | Not stated in licence record |
| Registration No. 131567 | Linka 300mg Injection | Vial of 1 ml injection | Not stated in licence record |
| Registration No. 123274 | Lincocin 600mg Injection (Pfizer Ltd) | Vial of 2 ml injection | Not stated in licence record |
Available forms across the listed licences include injections, capsules and syrups.
Safety Considerations
Contraindication relations in the knowledge graph (not label text): liver failure, Clostridium difficile colitis, perinatal necrotizing enterocolitis, colitis, digestive system disease and intestinal disease.
Drug Interactions: 21 interactions were found. Those rated Moderate:
- Balsalazide
- Picosulfuric acid
- Attapulgite
- Kaolin
- Erythromycin
- Ethinylestradiol
The remaining interactions have an unknown severity level, including warfarin, metformin, morphine, simvastatin, omeprazole, cimetidine, ranitidine, lidocaine, clotrimazole, lactulose, triamcinolone, cetirizine, montelukast and salmeterol.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No clinical trials or publications study lincomycin in polyclonal hyperviscosity syndrome, and no plausible mechanism links an antibacterial protein-synthesis inhibitor to this condition. The evidence level is L5.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator or manufacturers (needed for safety screening)
- Mechanism of action data from DrugBank
- Any preclinical or clinical study directly addressing polyclonal hyperviscosity syndrome
- Route compatibility and similarity-to-original-indication assessments, which are still pending
- Review of the gastrointestinal and liver-related contraindication relations before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.